Anaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents
No Thumbnail Available
Identifiers
Date
2018-05-01
Authors
Molina-Cuadrado, Emilio
Mateo-Carrrasco, Hector
Collado, Antonio
Martin, Marta Casado
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Bmj publishing group
Metrics
Export
Abstract
Objectives Anaemia is the most common side effect associated with ribavirin (RBV). This study intended to assess its incidence and determine its predictive factors in patients with hepatitis C virus on RBV plus direct-acting antiviral agents (DAAs).Methods A retrospective study of patients receiving RBV+DAA was conducted. Serum haemoglobin (Hb) was determined at baseline and monitored 4weekly. Anaemia was defined as a single occurrence of Hb
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
Ribavirin, Direct-acting antiviral, Anaemia, Predictor, Hepatitis C, Peginterferon, Telaprevir, Therapy, Combination, Alpha-2a